Venaxis, Inc. Prices $20.0 Million Public Offering of Common Shares

     Venaxis, Inc. Prices $20.0 Million Public Offering of Common Shares

PR Newswire

CASTLE ROCK, Colo., April 3, 2014

CASTLE ROCK, Colo., April 3, 2014 /PRNewswire/ --Venaxis, Inc. (NASDAQ:
APPY), an in vitro diagnostic company focused on obtaining FDA clearance for
and commercializing its CE Marked APPY1™ Test, a rapid, multiple
biomarker-based index assay for identifying patients that are at low risk for
appendicitis, today announced the pricing of an underwritten public offering
of 8,335,000 shares of its common stock at a price to the public of $2.40 per
share. In addition, Venaxis has granted the underwriters a 30-day option to
purchase up to an additional 1,250,250 shares of common stock solely to cover
over-allotments, if any. The offering is expected to close on or about April
8, 2014, subject to customary closing conditions.

Canaccord Genuity is acting as sole book-running manager for the offering and
Craig-Hallum Capital Group is acting as lead manager.

The net proceeds from the sale of the shares of common stock, after deducting
the underwriting discount and the other offering expenses, are expected to be
approximately $18.4 million. Venaxis intends to use the net proceeds from the
offering together with the Company's existing cash resources, for working
capital and other general corporate purposes, including overhead expenses
while the Company seeks FDA clearance for APPY1, for initial commercialization
activities of APPY1 in the U.S., for sales and marketing activities in the
E.U. and to advance product development activities to attempt to expand and
improve performance of the test.

The offering is being made pursuant to a shelf registration statement (File
No.333-191853) previously filed with and declared effective by the U.S.
Securities and Exchange Commission (SEC). A preliminary prospectus supplement
and accompanying prospectus related to the offering was filed with the SEC on
April 2, 2014. A final prospectus supplement and accompanying prospectus
relating to the offering will be filed with the SEC. Electronic copies of the
prospectus supplement and accompanying prospectus can be obtained through the
website of the SEC at When available, copies of the prospectus
supplement and the accompanying prospectus relating to the offering may also
be obtained by contacting the Syndicate Department of Canaccord Genuity Inc.,
by mail at 99 High Street, 12th Floor, Boston, Massachusetts 02110, or by
telephone at (800)225-6201. Prospective investors should read in their
entirety the prospectus supplement and the accompanying prospectus and the
other documents that Venaxis has filed with the SEC for more complete
information about Venaxis and the offering.

This press release does not constitute an offer to sell or a solicitation of
an offer to buy any securities, nor shall there be any sale of these
securities in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the securities laws
of any such jurisdiction. This offering may be made only by means of a
prospectus supplement and accompanying base prospectus.

About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical
development and commercialization of its CE Marked APPY1 Test, the Company's
rapid, protein biomarker-based assay for appendicitis. This unique
appendicitis test has projected high sensitivity and negative predictive value
and is being developed to aid in the identification of patients at low risk
for acute appendicitis, allowing for more conservative patient management.
The APPY1 Test is being developed initially for pediatric, adolescent and
young adult patients with abdominal pain, as this population is at the highest
risk for appendicitis and has the highest risk of long-term health effects
associated with CT imaging. While FDA clearance is being sought, a limited
commercial launch for the APPY1 Test is ongoing in select European countries.
For more information, visit

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc.
("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All
statements, other than statements of historical fact, included in this press
release that address activities, events or developments that Venaxis believes
or anticipates will or may occur in the future are forward-looking
statements. These statements are based on certain assumptions made based on
experience, expected future developments and other factors Venaxis believes
are appropriate in the circumstances. Such statements are subject to a number
of assumptions, risks and uncertainties, many of which are beyond the control
of Venaxis. Investors are cautioned that any such statements are not
guarantees of future performance. Actual results or developments may differ
materially from those projected in the forward-looking statements as a result
of many factors, including our ability to obtain FDA clearance or approval,
maintain CE Marking, cost effectively manufacture and generate revenues from
the APPY1  Test at a profitable price point, execute agreements required to
successfully advance the company's objectives, retain the management team to
advance the products, overcome adverse changes in market conditions and the
regulatory environment, obtain and enforce intellectual property rights, and
realize value of intangible assets. Furthermore, Venaxis does not intend (and
is not obligated) to update publicly any forward-looking statements. The
contents of this press release should be considered in conjunction with the
risk factors contained in Venaxis' recent filings with the SEC, including its
Form 10-K for the year ended December 31, 2013, filed with the SEC on March
28, 2014.

Venaxis and APPY1 are trademarks of Venaxis, Inc.

For Investors and Media:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, PhD,; (212) 375-2664
Claire Sojda,; (212) 375-2686

SOURCE Venaxis, Inc.

Press spacebar to pause and continue. Press esc to stop.